

INCEPT: The Intensive Care Platform Trial—Design and protocol

Anders Granholm^{1,2,3}  | Morten Hylander Møller^{1,3,4} | Benjamin Skov Kaas-Hansen^{1,2,3}  | Aksel Karl Georg Jensen^{1,2,3} | Marie Warrer Munch^{1,3}  | Maj-Brit Nørregaard Kjær^{1,3}  | Lars Wiuff Andersen^{5,6,7}  | Olav Lilleholt Schjørring^{3,8,9}  | Bodil Steen Rasmussen^{3,8,9}  | Tine Sylvest Meyhoff^{1,3}  | Rikke Faebo Larsen^{1,3} | Hans-Christian Thorsen-Meyer^{1,3} | Marie Oxenbøll Collet^{1,3,4}  | Nick Frørup Meier^{1,3}  | Stine Estrup^{1,3} | Ole Mathiesen^{3,4,10}  | Mathias Maagaard¹⁰  | Lone Musaeus Poulsen^{3,10} | Thomas Strøm^{3,11,12} | Steffen Christensen^{5,6} | Camilla Rahbek Lysholm Bruun¹ | Frederik Keus^{3,13} | Peter Rossing^{4,14} | Asger Granfeldt^{5,6} | Anne Craveiro Brøchner^{3,15}  | Theis Skovsgaard Itenov^{3,4,16} | Maria Cronhjort^{3,17,18} | Jon Henrik Laake^{3,19,20} | Johanna Hästbacka^{3,21} | Carmen Andrea Pfortmueller^{3,22} | Martin Siegemund^{3,23}  | Martin Ingi Sigurdsson^{3,24,25} | Lars Peter Kloster Andersen^{4,10} | Davide Placido^{1,26} | Theis Lange^{2,3}  | Anders Perner^{1,3,4}

Correspondence

Anders Granholm, Department of Intensive Care 4131, Copenhagen University Hospital—Rigshospitalet, Blegdamsvej 9, DK-2100, Copenhagen, Denmark.
Email: andersgran@gmail.com; anders.granholm@regionh.dk

Funding information

Dagmar Marshalls Fond; Grosserer Jakob Ehrenreich og Hustru Grete Ehrenreichs Fond; Sygeforsikringen 'danmark'; Novo Nordisk Fonden; Danmarks Frie Forskningsfond; Savværksejer Jeppe Juhl og hustru Ovita Juhls Mindelegat

Abstract

Background: Adult intensive care unit (ICU) patients receive many interventions, but few are supported by high-certainty evidence. Randomised clinical trials (RCTs) are essential for trustworthy comparisons of intervention effects, but conventional RCTs are costly, cumbersome, inflexible, and often turn out inconclusive. Adaptive platform trials may mitigate these issues and have higher probabilities of obtaining conclusive results faster and at lower costs per participant.

Methods: *The Intensive Care Platform Trial (INCEPT)* is an investigator-initiated, pragmatic, randomised, embedded, multifactorial, international, adaptive platform trial including adults acutely admitted to ICUs. *INCEPT* will assess comparable groups of interventions (primarily commonly used interventions with clinical uncertainty and practice variation) nested in domains. Interventions may be either open-label or masked. New domains will continuously be added to the platform. *INCEPT* assesses multiple core outcomes selected following substantial stakeholder involvement:

For affiliations refer to page 10

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2025 The Author(s). *Acta Anaesthesiologica Scandinavica* published by John Wiley & Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation.

mortality, days alive without life support/out of hospital/free of delirium, health-related quality of life, cognitive function, and safety outcomes. Each domain will use one of these core outcomes as the primary outcome. *INCEPT* primarily uses Bayesian statistical methods with neutral, minimally informative or sceptical priors, adjustment for important prognostic baseline variables, and calculation of absolute and relative differences in the intention-to-treat populations. Domains and intervention arms may be stopped for superiority/inferiority, practical equivalence, or futility according to pre-specified adaptation rules evaluated using statistical simulation or at pre-specified maximum sample sizes. Domains may use response-adaptive randomisation, meaning that more participants will be allocated to interventions with higher probabilities of being superior.

Conclusions: *INCEPT* provides an efficient, pragmatic, and flexible platform for comparing the effects of many interventions used in adult ICU patients. The adaptive design enables the trial to use accumulating data to improve the treatment of future participants. *INCEPT* will provide high-certainty, conclusive evidence for many interventions, directly inform clinical practice, and thus improve patient-important outcomes.

KEYWORDS

adaptive platform trial, intensive care, randomised clinical trial, trial protocol

1 | INTRODUCTION

The most critically ill patients are admitted to intensive care units (ICUs) where they are treated with life supportive therapies, for example, advanced respiratory and circulatory support and renal replacement therapy (RRT). Each year, approximately 25,000–30,000 patients are admitted to ICUs in Denmark.¹ Due to demographic changes, this is expected to increase in the coming years.² Approximately 1 in 5 ICU patients die within 30 days,¹ and those who survive go through long hospital stays and recovery periods and experience decreased health-related quality of life (HRQoL). ICUs consume vast amounts of healthcare and financial resources,³ and critical illness is thus a huge burden on patients, their family members, and society.⁴ Of the many interventions used in ICUs, only approximately 10% are supported by high-certainty evidence.⁵ Concerningly, randomised clinical trials (RCTs) of ICU interventions often show either harm or lack of clinically relevant effects, and *increases* in mortality with interventions thought to be beneficial are found almost as often as *decreases*.^{6, 7} Consequently, multiple recent RCTs have led to de-implementation of interventions already used clinically.⁸

While RCTs of ICU interventions already in use or new ones are warranted, there are limitations in conventional RCTs (i.e., stand-alone, parallel-group RCTs comparing two interventions at a time with limited flexibility, fixed sample sizes, and dichotomised conclusions based on conventional, frequentist statistical methods).⁹ Most RCTs of ICU interventions are inconclusive, as they do not show firm superiority of one intervention^{6, 10} and often do not formally assess practical equivalence. This is often, at least partly, explained by over-

optimistic assumed effect sizes and incorrect assumptions about baseline outcome distributions,^{11–15} leading to RCTs that are unable to provide firm conclusions regarding smaller, yet clinically important intervention effects. Unfortunately, inconclusive RCTs are at risk of being erroneously interpreted as if there are no differences between interventions.^{12, 16} Ultimately, this poses a risk of research waste and patient harm.

Adaptive platform trials¹⁷ may remedy some of the challenges with conventional RCTs and are receiving increased interest,^{18, 19} also in the ICU setting.²⁰ Adaptive platform trials focus on a *population* (defined by a setting or condition) instead of specific *interventions*, with many interventions assessed on the same platform trial.¹⁷ Comparable interventions may be nested in so-called *domains*,¹⁷ and adaptive platform trials may run perpetually with new interventions or domains added continuously.¹⁷ Adaptive platform trials may use frequent adaptive (interim) analyses and make multiple adaptations based on accrued data.¹⁷ These include early dropping of arms, stopping whenever the evidence is certain enough, and response-adaptive randomisation, where accrued data are used to update allocation probabilities to increase chances that future participants will receive interventions that with higher probabilities will lead to better outcomes.^{17, 21} As adaptive platform trials typically run longer than stand-alone trials and use the same infrastructure, improving trial infrastructure (e.g., by automating data collection) and involving stakeholders can be more feasible than in shorter-running stand-alone trials. By planning for the inclusion of many participants while increasing flexibility to ensure stopping as soon as the evidence is sufficiently strong, adaptive trials can be designed to have higher probabilities of

obtaining conclusive answers without being too large, ensuring that results can benefit other patients as early as possible and that research resources are used optimally.²² Due to both the adaptations and the continuous use of the same trial infrastructure, adaptive platform trials may thus provide higher probabilities of conclusive answers while being more efficient and cost-effective than multiple stand-alone trials addressing the same questions.^{17, 22, 23} Taken together, adaptive platform trials thus convey ethical, practical, and economical benefits and may be more compelling to patients, clinicians, and other stakeholders.^{9, 17, 23–26} This is the motivation behind the *Intensive Care Platform Trial (INCEPT)*.

2 | METHODS

2.1 | Trial design and approvals

INCEPT is an investigator-initiated, pragmatic, randomised, embedded, multifactorial, international, domain-based adaptive platform trial focused on—but not restricted to—commonly used interventions where there is equipoise and practice variation due to uncertainty about which intervention is better.

INCEPT is governed by a *core protocol with domain-specific appendices* describing specific interventions and methodological choices for each domain. The core protocol has been preceded by substantial methodological work,²⁷ and extends the protocol for the adaptive Bayesian *Empirical Meropenem versus Piperacillin/Tazobactam for Adult Patients with Sepsis (EMPRESS)* trial.²⁸

The current, first approved (version 1.3) and all future approved versions of the full core protocol and domain-specific appendices will be available at the trial website (www.incept.dk); additional details, complete definitions, and completed reporting checklists (*Standard Protocol Items: Recommendations for Interventional Trials [SPIRIT]*²⁹ and *Consolidated Standards Of Reporting Trials, Adaptive designs Extension [CONSORT-ACE]*³⁰) can be found in these documents.

2.2 | Trial conduct, consent, and approvals

INCEPT will be conducted according to the approved core protocol and domain-specific appendices and will adhere to the applicable legislation (including that for clinical trials conducted in emergency situations^{31, 32}), the Helsinki declaration,³³ the International Conference on Harmonization Good Clinical Practice guidelines,³⁴ and the World Health Organization's guidance for best practices for clinical trials.³⁵

Informed consent prior to enrolment in *INCEPT* is not possible due to acute critical illness, and thus, enrolment will generally be without prior consent,^{31, 32} followed by informed consent to continue in each domain (and inclusion in other domains that may become relevant during the same ICU stay) from legal surrogates and participants as soon as possible. Consent for participation may be withdrawn at

any time without explanation and may be withdrawn for specific domains only. If consent is withdrawn, we will ask for permission to continue data registration.

INCEPT has been approved by the competent authorities and publicly registered before initiation (approvals and identifiers: EUCT number: 2024-516208-41-00; ClinicalTrials.gov identifier: NCT06667999; Universal Trial Number: U1111-1313-8171). Additional local/national approvals will be obtained as required, and new domains added to the platform will similarly be approved before initiation.

2.3 | Eligibility criteria

Adults (≥ 18 years old) acutely admitted to the ICU may be included if they are eligible for one or more active domain(s). Patients will be excluded if informed consent is expected to be unobtainable following inclusion or if they are under coercive measures. Additional specific eligibility criteria will apply for each domain. Patients may be included in *INCEPT* multiple times during separate ICU stays, but only randomised once to each domain.

2.4 | Domains, interventions, and co-enrolment

Comparable interventions will be nested in domains¹⁷ (Figure 1), which conceptually resemble what could be compared in a stand-alone trial. Domains will continuously be added to the platform; however, each domain will be *closed*,²⁴ that is, new interventions will not be added to existing domains once started. Interventions in domains may be open-label or masked, that is, blinded to participants and personnel. This will be described, along with rationales, in the domain-specific appendices. In cases where simultaneous enrolment in multiple specific domains is not considered appropriate (e.g., domains with overlapping interventions or interventions targeting the same organ systems), this will be specified along with a priority list in the domain-specific appendices. All co-interventions not assessed in active domains will be at the discretion of treating clinicians. Currently, the domains outlined in Figure 1 have been approved or are being planned for submission for approval later. *INCEPT* allows and prioritizes simultaneous enrolment in as many domains as possible. Co-enrolment with other interventional trials is generally supported and permitted after approval by the management committee.

2.5 | Outcomes

All *INCEPT* domains will assess the *core outcomes* outlined in Table 1. Additional outcomes may be assessed in specific domains. The *INCEPT* core outcomes are based on a core outcome set for adult general ICU patients developed as part of *INCEPT* and with extensive stakeholder involvement.⁴² The exact definitions and tools have been specified by




FIGURE 1 Multiple domains in an adaptive platform trial, with the domains and interventions reflecting the tentative first domains and interventions on *INCEPT*. Each domain consists of comparable interventions (similar to what could be compared in a single stand-alone trial), and all domains use the same overall platform trial infrastructure. All domains use the same overall platform eligibility criteria, and the overall eligible population thus consists of adult, acutely admitted ICU patients. Additional domain-specific inclusion criteria further narrow down this population, for example, the albumin domain will be restricted to patients with shock, the thromboprophylaxis domain to patients with an indication for thromboprophylaxis with LMWH, and the glucose domain to patients with an insulin requirement for blood glucose management. Randomisation to the interventions in each domain is separate. Collection of data, including outcome data, is joint across domains. Based on adaptive (interim) analyses of outcome data, domains will adapt by changing the available interventions and domains and by adapting allocation probabilities, as described in the text and full core protocol available at the trial website. Domains will be stopped once there is sufficiently strong evidence for a conclusion according to pre-defined criteria or at a pre-specified maximum sample size. Additional details on all *INCEPT* domains will be specified in domain-specific appendices to the core protocol. At the time of writing, the albumin domain has been approved, while the other domains illustrated are under preparation and have not yet been submitted for approval. CGM: continuous glucose monitoring; ICU: intensive care unit; *INCEPT*: the Intensive Care Platform Trial; LMWH: low-molecular weight heparin.

the *INCEPT* management committee, as the associated *core outcome measurement set*^{42, 43} has not yet been developed. For each domain, the *primary* outcome and the *guiding* outcome (the outcome used for all adaptations as described below) must be one of the core outcomes, except HRQoL, cognitive function, and domain-specific safety outcomes. Domains will generally use the same *primary* and *guiding* outcome, but different domains may use different core outcomes as primary and guiding outcomes if relevant (e.g., the same outcome after different follow-up durations may be used as the guiding and primary outcomes, respectively, to facilitate faster adaptations). Staff assessing HRQoL and cognitive function will always be blinded to allocation.

2.6 | Randomisation and allocation concealment

Randomisation will be separate and independent in each domain via an electronic system ensuring concealed allocation. Domains may use either fixed allocation probabilities, response-adaptive randomisation (meaning that participants will have higher probabilities of being allocated to interventions with higher probabilities of being superior²¹), or combinations (e.g., a fixed allocation probability to a common control arm, if any, and response-adaptive randomisation in non-control arms).²¹ When response-adaptive randomisation is used, allocation probabilities will be updated after adaptive analyses according to the probabilities of each arm being overall superior; response-adaptive

TABLE 1 INCEPT core outcomes.

Outcome	Definition and operationalization
All-cause 30-day mortality	All-cause, fixed-time mortality
All-cause 90-day mortality	
All-cause 180-day mortality	
Days alive without life support at day 30 ^a	Days alive without invasive mechanical ventilation, continuous use of vasopressors/inotropes, use of RRT (continuously or intermittently, including up to 3 days between intermittent RRT) at hospitals
Days alive without life support at day 90 ^a	
Days alive out of hospital at day 30 ^a	Days alive and out of hospital ^b
Days alive out of hospital at day 90 ^a	
Days free of delirium at day 30 ^a	Days are <i>not</i> considered free of delirium in case of any of the following: (1) any registered positive delirium score with a validated screening tool ^c (2) new treatment with antipsychotics ^d (3) delirium not evaluable due to mortality or registered coma ^e
EQ-5D-5L index values ³⁶ (HRQoL) at day 180	EQ-5D-5L index values, primarily calculated using national value sets, and with non-survivors assigned 0 (corresponding to a HRQoL as bad as being dead) ^f
EQ VAS ³⁶ (HRQoL) at day 180	EQ VAS with non-survivors assigned 0 (worst possible value) ^f
Cognitive function at day 180	Assessed using the <i>Montreal Cognitive Assessment test 5-minute version</i> , v2.1 ("Mini MoCA"), ^{37, 38} with non-survivors assigned 0 (worst possible value) ^f
One or more domain-specific safety outcomes ⁸	Number of participants with one or more safety outcomes specified in the domain-specific appendices according to a risk proportionate approach ³⁹ and considerations about which safety outcomes are clinically most relevant

Note: Core outcomes assessed in all INCEPT domains. Complete definitions with additional details are available in the full core protocol, along with *mock tables* illustrating how outcome data from the final and adaptive analyses will be presented.

Abbreviations: HRQoL, health-related quality of life; INCEPT, the Intensive Care Platform Trial; RRT, renal replacement therapy.

^aReported in two versions: non-survivors assigned 0 (as most commonly done⁴¹ to ensure that mortality is the worst possible outcome) and actual values without penalizing mortality.⁴⁰ The primary versions will be specified for each domain.

^bDays in rehabilitation facilities and nursing homes will not count as days in hospitals.

^cA list of accepted screening tools is included in the full core protocol.

^dAny administration of haloperidol, olanzapine, or quetiapine in participants not receiving either of these at index hospital admission.

^eA list of scales and cutoffs used to define coma is included in the full core protocol.

^fSecondary analyses will be conducted in survivors only.

⁸The maximum follow-up period must cover at least the interventional period; for domains using a primary/guiding outcome with a shorter follow-up duration than the maximum interventional period, this outcome will additionally be reported after a follow-up duration corresponding to the follow-up duration for the primary/guiding outcome.

TABLE 2 Baseline variables.

Characteristic
Country of enrolment <i>[Each participating country will be listed]</i>
Age (years)
Sex Female Male
Weight (kg)
Height (m)
Use of invasive mechanical ventilation
Use of vasopressors/inotropes
Use of RRT
Limitations of care
Co-existing conditions Active haematological malignancy or metastatic cancer History of ischaemic heart disease or heart failure Diabetes mellitus Chronic pulmonary disease Chronic liver disease Known use of immunosuppressive therapy within the last 3 months Previous organ transplantation Chronic use of RRT Treatment with antipsychotics at hospital admission
Acute surgery within 7 days prior to randomisation
SMS-ICU ^a
Clinical Frailty Scale ^b
Lowest systolic blood pressure in the 24 h preceding randomisation (mmHg)
Highest plasma lactate in the 24 h prior to randomisation (mmol/L)
Highest plasma creatinine in the 24 h prior to randomisation (µmol/L)

Note: Baseline data assessed in all INCEPT domains. Variables are binary unless stated otherwise. Complete definitions with additional details are available in the full core protocol, along with a generic *mock table* illustrating how baseline data will be presented.

Abbreviations: mmHg, millimetres of mercury; mmol/L, millimoles per litre; RRT, renal replacement therapy; SMS-ICU, Simplified Mortality Score for the Intensive Care Unit⁴⁶; µmol/L, micromoles per litre.

^aSMS-ICU⁴⁶ is a severity score ranging from 0 to 42 points, with higher scores indicating more severe illness and higher risks of death.

^bInvestigator-assessed clinical frailty, using the Clinical Frailty Scale v2.0.^{47, 48} Values range from 1 (very fit) to 9 (terminally ill).

randomisation may be restricted to avoid over-aggressive adaptations to random fluctuations (Section 2.12).^{21, 44}

Domains using response-adaptive randomisation will generally use block randomisation stratified by site (and possibly additional anticipated important baseline prognostic factors) prior to the first adaptive analysis, followed by simple, unstratified randomisation.⁴⁵ Domains using fixed randomisation only will generally use block randomisation stratified by site (and possibly additional baseline variables) throughout the enrolment.

2.7 | Baseline data, process data, separation, and feasibility

The baseline characteristics outlined in Table 2 will be registered and presented for all domains; in addition, domains may register and present additional relevant baseline data. Relevant process data (including data on protocol adherence) will be registered in each domain and may be used to assess separation between arms where relevant. Domains may use formal feasibility phases with pre-defined feasibility criteria.

2.8 | Statistical framework and general statistical considerations

INCEPT will primarily use Bayesian statistical methods⁴⁹ for adaptive and final analyses, as this approach is well-suited and commonly used for advanced adaptive trials^{9, 17, 18, 50} and has interpretational advantages.⁴⁹ Specific domains may use conventional, frequentist statistical methods with no or few adaptations. Members of the statistical analysis team will be unblinded and will not participate in screening, inclusion, intervention delivery, or outcome assessment to avoid any potential influence on decisions regarding enrolments, treatment, or outcome assessment.⁵¹ In addition, statistical analysis plans will be very detailed, and analysis scripts will be prepared using simulated data prior to initiating domains. The primary conclusions in each domain will be based on whether a stopping rule (Section 2.11) is ultimately triggered, and interpretations will in any case be probabilistic.

2.9 | Analysis sets, comparisons, and estimands

Analyses will primarily be conducted in full analysis sets according to the intention-to-treat principle, that is, all randomised participants except those without consent to the use of *any* data (except if specified otherwise, with motivations, for specific domains). Patients erroneously randomised to blinded domains may be excluded if they have not received the allocated intervention and are excluded before unblinding and analysis.⁵² Additional analyses may be conducted using other analysis sets (e.g., per-protocol populations).

In domains with >2 arms, arms may either be compared simultaneously *all versus all* or pairwise against a *common control arm*.^{17, 21} Domains using a control arm (i.e., an arm corresponding to usual care or placebo) may be analysed using either strategy, generally informed by statistical simulation.⁴⁴ Participants will only be compared with participants randomised in the same domain. As *INCEPT* domains are *closed* and *staggered entry* is not permitted, participants will thus only be compared with *concurrently* randomised participants, thereby avoiding potential biases due to the use of non-concurrent controls.⁵³

Key attributes (population, interventions, outcome, summary measure, and handling of intercurrent events) for the primary estimand in each domain,^{54, 55} and thus the questions primarily answered will be clearly specified in domain-specific appendices.

2.10 | Adaptive analyses

The timing and frequency of adaptive (interim) analyses will be specified for each domain. Adaptive analyses will be conducted at specified times (e.g., the first workday of the month) whenever a pre-specified number of participants has completed their outcome-data lag period,⁵⁶ defined as the follow-up duration of the guiding outcome plus a 15-day data collection/verification period. Adaptive analyses will include all participants who have completed their outcome-data lag period; that is, participants with outcome data available who have not completed the period will not be analysed.

2.11 | Adaptation rules

Most *INCEPT* domains will use stopping rules based on Bayesian probabilities as outlined in this section, but other stopping rules (including, e.g., conventional group sequential monitoring boundaries⁵⁷) may be used in specific domains.

Domains may be stopped, and arms may be dropped, for either inferiority/superiority (mandatory), practical equivalence (optional), or futility (optional, only in domains with comparisons against a *common control arm*),²¹ based on the posterior probabilities for analyses of the *guiding* outcome and pre-defined thresholds, with all stopping rules being binding.⁵¹

2.11.1 | Adaptation rules in domains simultaneously comparing all arms

For domains simultaneously comparing all arms, arms will be dropped for inferiority if the posterior probability that an arm is overall best is below a pre-specified threshold.^{21, 44} Similarly, if the probability that a single arm is overall best exceeds a pre-specified threshold, the domain will be stopped and that arm declared superior.^{21, 44} Domains may be stopped for practical equivalence if the absolute difference between all remaining active arms is less than a pre-defined size according to a pre-defined probability threshold.^{21, 44}

2.11.2 | Adaptation rules in domains with pairwise comparisons against a common control

For domains with pairwise comparisons of interventional arms against a common control arm, non-control arms will be dropped for inferiority if the probability that they are better than the common control is below a pre-specified threshold.^{21, 44} If the probability that a non-control arm is superior to the common control arm exceeds a pre-specified threshold, the common control arm will be dropped, and the superior non-control arm promoted to be the new control (if multiple non-control arms are superior in the same analysis, the one with the highest probability of being overall superior will become the new control).^{17, 21, 44} A domain will be stopped for superiority when only one

arm remains after dropping the last comparator for inferiority. In domains with a common control arm, non-control arms may be dropped for practical equivalence if the absolute difference compared to the common control arm is less than a pre-defined size according to a pre-defined probability threshold. Similarly, non-control arms may be dropped for futility if they are not superior by a pre-specified amount compared to the common control arm according to a pre-specified probability threshold.^{21, 44} Assessments of practical equivalence and/or futility may be conducted against the original common control arm only or also against other arm(s) promoted to be the common control arm.

2.11.3 | Other considerations

Whenever arms are dropped in domains without a common control arm or whenever a common control arm is replaced, analyses will be immediately repeated, as this will lead to updated probabilities for the remaining comparisons that in turn may lead to stopping rules being triggered for additional arms. Domains will be declared inconclusive if they reach the maximum sample size without triggering applicable stopping rules. Whenever domains are stopped, all remaining randomised participants will be followed up, and a final analysis conducted. The primary conclusion (superiority/inferiority, practical equivalence, futility, or inconclusiveness) will be based on the last adaptive analysis, while the primary estimates and probabilities presented will be from the final analysis, including data from all randomised participants.

Stopping rules for superiority and inferiority will generally be calibrated using statistical simulation^{9, 21, 44} to obtain an overall type 1 error rate for the guiding outcome of $\leq 5\%$ (i.e., there will be $\leq 5\%$ probability of stopping for superiority if there are no between-arm differences).

2.12 | Randomisation rules

Domains may use either fixed allocation profiles (with appropriate rescaling if arms are dropped), response-adaptive randomisation,^{21, 57} or combinations hereof. For domains with two arms or all arms compared simultaneously, we will generally use initial equal allocation followed by either fixed equal allocation or response-adaptive randomisation. For domains comparing interventional arms against a common control arm, we will generally use a fixed and relatively higher control arm allocation probability (e.g., square-root to number of non-control arms to 1-ratios²¹), and either response-adaptive randomisation or fixed allocation probabilities in the remaining arms. When response-adaptive randomisation is used, this will be based on the probabilities of each arm being overall superior,^{21, 44, 58} and restrictions (minimum/maximum limits on probabilities and/or use of a *softening factor* making allocation probabilities more similar than the raw probabilities of each arm being superior^{21, 44}) may be used to avoid over-aggressive adaptations to random fluctuations and mitigate the potential undesirable effects on performance metrics that

may be seen in some cases. Exact randomisation rules will be specified separately for each domain.

2.13 | Analyses

2.13.1 | Descriptive data

Baseline, process, and outcome data will be presented descriptively in each arm in each domain. Numerical data will be summarized using medians with interquartile ranges (IQRs) and categorical variables as counts with percentages.

2.13.2 | Analysis models, priors, and presentation of results

Analyses will generally use Bayesian logistic and linear regression models adjusted for the stratification variables used and several additional anticipated important prognostic baseline variables to increase precision and account for potential baseline imbalances⁵⁹: site, age, sex, active hematologic malignancy or metastatic cancer, acute surgery within 7 days prior to randomization, invasive mechanical ventilation, circulatory support (continuous infusion of vasopressors/inotropes), RRT within 72 h prior to randomization, and time period (categorical; used in all domains using arm dropping or response-adaptive randomisation, with a new period defined following each adaptation). Continuous variables will be modeled using linear and quadratic terms on the model scale to allow for non-linearity.

We will generally use neutral priors (i.e., priors not favouring any intervention) for the intervention effects and all adjustment variables in the primary analyses. Priors for the intervention effects will generally be weakly informative or slightly to moderately sceptical, which limits the influence of random fluctuations early.⁶⁰ Sensitivity analyses using other priors (e.g., more informative/sceptical priors, evidence-based priors, or expert-elicited priors^{49, 61}) will generally be conducted. Exact priors will be specified in each domain-specific appendix.

Results will be presented as sample-average (marginal) absolute differences (risk differences/mean differences; primary summary measures) and relative differences (risk ratios/ratios of means; secondary summary measures) using a robust G-computation-based approach.⁵⁹ Posteriors will be summarised using median values as point estimates, with 95% percentile-based credible intervals and graphical presentation of full posterior distributions for the absolute and relative differences and the expected probabilities or mean values with each intervention. Probabilities of superiority/inferiority of all arms (overall and/or pairwise/compared to a common control) will be presented, as will all probabilities relevant for any stopping rules for practical equivalence and/or futility.

Model fitting and assessment of model adequacy are described in the full protocol. Relevant sensitivity analyses will be pre-specified in each domain-specific appendix or conducted post hoc if relevant.

2.13.3 | Heterogeneous intervention effects and interactions

The primary and adaptive analyses in *INCEPT* focus on average intervention effects, which drive all adaptations. However, potential heterogeneous intervention effects^{9, 62} will generally be assessed once domains close; exact plans for assessing heterogeneous intervention effects (i.e., baseline characteristics considered and the exact methodological approach) will be pre-specified for each domain. Similarly, where deemed relevant, we will pre-specify plans for assessing potential between-domain interactions.

2.13.4 | Missing data handling

Missingness is expected to be limited for most variables and outcomes (except HRQoL and cognitive function, where moderate amounts are expected⁴¹) due to the variables selected and continuous monitoring of missingness in the electronic case report form (eCRF). Total and intervention-specific missingness will be presented, and all analyses will be conducted after multiple imputation of missing data.⁶³ We will assume that data are missing at random and impute 25 datasets separately in each intervention group using the predictive mean matching method for numerical variables and binary/ordinal/polytomous logistic regression methods for binary/ordinal/nominal variables, respectively.⁶³ All variables included in the analyses and relevant additional baseline data (specified in the domain-specific appendices) will be included in the imputation models for the final analyses; the imputation models for the adaptive analyses will be simplified and will include all adjustment variables, the guiding outcome, and mortality after the same follow-up as the guiding outcome. Partially available data will be used to the extent possible. Supplementary best-worst/worst-best case sensitivity analyses⁶⁴ may be used, as defined in the domain-specific appendices.

2.13.5 | Statistical simulation and performance metrics

Domain designs will be evaluated with statistical simulations using the *adaptr*⁶⁵ R package ([inceptdk.github.io/adaptr](https://github.com/inceptdk/adaptr)), developed as part of *INCEPT*, and according to the principles described elsewhere.^{21, 44} In brief, performance metrics of the final design and several variations will be evaluated under multiple clinical scenarios (always including a scenario with no differences between arms and multiple scenarios with between-arm differences present, for example, small and large differences) using 100,000 simulations under each scenario for the final design.^{21, 44} The influence of key assumptions underlying the simulations (e.g., the reference distribution of the guiding outcome and the expected inclusion rates) will be assessed in sensitivity analyses.⁴⁴

Multiple performance metrics, including expected sample sizes, will be calculated to cover both practical/logistical/economical

aspects, benefits to participants and external patients, and accuracy, and presented for the final design and the evaluated sensitivity analyses.^{21, 44} As a general principle, domains in *INCEPT* will be required to have at least a 90% probability of conclusiveness, that is, of triggering a stopping rule at or before the maximum permitted sample size for the final design across all clinical scenarios (evaluated according to the primary assumptions regarding the reference distribution and expected inclusion rates⁴⁴).

2.14 | Stakeholder involvement

Involvement of key stakeholders, including former patients and members of the public, is central in *INCEPT*. To ensure the relevancy of *INCEPT* to those who will ultimately be affected by or use its results, involvement throughout the various research stages is prioritized as recommended.^{35, 66} Stakeholder involvement is ensured through a central advisory board to *INCEPT* and multiple local research panels. A description of stakeholder involvement so far, along with a description of the minimum requirements for stakeholder involvement in *INCEPT* going forward, is presented in the full core protocol.

2.15 | Data collection and embedding

INCEPT will use a customised eCRF for inclusion, randomisation, and data collection. The eCRF will support hybrid data entry, that is, manual data entry and automated data collection from electronic patient records. Automated data collection will be expanded over time to support additional data points and electronic patient records, reducing the resource burden from manual data entry. We aim to later build embeddings within electronic patient records to allow automatic notifications to clinicians and research staff regarding eligible patients, outcomes (including safety outcomes), and more.

2.16 | Organisational aspects, independent data monitoring and safety committees, and monitoring

INCEPT is governed by a platform management committee led by the platform sponsor, with the involvement of representatives from the partnering organisations/regions/countries and active domains. The platform management committee receives advice or obtains input from the competent authorities, funders, and key stakeholders via the advisory board and research panels or directly. Daily management of each domain is the responsibility of a domain management committee, chaired by a domain sponsor, that refers to the overall platform management committee.

Each domain has its own multidisciplinary independent data monitoring and safety committee (IDMSC), responsible for overseeing domain conduct and participant safety, including during annual safety meetings. IDMSCs will be advisory to the domain/platform management committees, and an IDMSC charter will be outlined for each

domain. Of note, IDMSCs will not conduct the regular adaptive analyses, but will be updated about their results.

INCEPT and all domains will be externally monitored according to the *Good Clinical Practice* directive, with monitoring plans developed in collaboration with the *GCP unit of Copenhagen University Hospital*. In addition, trial and domain progress will be centrally monitored to optimize data quality and protocol adherence.

2.17 | Dissemination

All results of all domains will be published in international peer-reviewed medical journals, the applicable trial registers, and the trial website, with domain reports following the *CONSORT-ACE* guideline.³⁰ Generally, we aim to make results public on pre-print servers simultaneously with submission for publication, although we may deviate from this in some instances.

3 | DISCUSSION

INCEPT is an investigator-initiated, pragmatic, randomised, embedded, multifactorial, international, domain-based (primarily) Bayesian adaptive platform trial including adults acutely admitted to the ICU. *INCEPT* may run perpetually and intends to assess many interventions, primarily focusing on interventions in common use where there is practice variation due to a lack of high-certainty evidence about which intervention is better.

3.1 | Strengths

INCEPT comes with multiple strengths. First, it will be conducted in many ICUs across many countries, increasing the total number of eligible patients and ensuring generalizability and external validity. Currently, inclusion is planned in Denmark, the Netherlands, Sweden, Norway, Switzerland, Finland, and Iceland. Second, by being a potentially perpetual platform trial, *INCEPT* makes the establishment of a lasting infrastructure and *embedding* in both clinical practice and within electronic patient records feasible, which will facilitate (partially) automated data collection, decreasing the labor and cost per randomized participant. Third, *INCEPT* will be pragmatic, with co-interventions administered at the discretion of the treating clinicians, and with support for co-enrollment with other RCTs. Fourth, combining large maximum sample sizes with adaptive features will ensure high probabilities of obtaining conclusive results to directly inform clinical practice without risking that domains become *too large*. In addition, adaptive arm dropping and response-adaptive randomization (where used) allow domains to *continuously learn* from the accumulating evidence *before* a stopping decision is triggered, which is central to a *learning healthcare system*.⁶⁷ Adaptive arm dropping increases

efficiency by dropping inferior (or equivalent or futile) arms early. Whenever inferior arms are dropped early, the probabilities of better outcomes for future participants are increased.^{17, 21} Similarly, response-adaptive randomization increases the probabilities that future participants will be allocated to superior interventions.^{17, 21} Fifth, *INCEPT* primarily uses Bayesian statistical methods, and results will be interpreted probabilistically and nuanced regardless of whether any formal stopping rules are triggered, to embrace any uncertainties without misinterpretation. Sixth, *INCEPT* is based on a comprehensive and thorough framework for planning domains, with the central design features and assumptions evaluated using extensive statistical simulation.^{21, 44} This ensures an optimal trade-off between the pros and cons of various design features, for example, the benefits of adaptive features for individual participants and external patients, and the efficiency of each domain will be carefully evaluated, and potentially negative implications of overly aggressive adaptations will be avoided. Seventh, extensive stakeholder involvement in *INCEPT* ensures the relevancy of trial results to patients, family members, clinicians, researchers, and other key stakeholders. Importantly, all domains will assess highly patient-important core outcomes selected through comprehensive stakeholder involvement,⁴² and the guiding/primary outcome in each domain will always be one of these core outcomes.

3.2 | Limitations

INCEPT comes with limitations, too. First, as maximum sample sizes in most domains are expected to be substantially larger than the *expected* sample sizes^{21, 44} and often larger than typical ICU RCTs,⁶⁸ the planning and funding of domains is more complex than for most typical stand-alone trials. This is, however, unavoidable to ensure high probabilities of conclusiveness, so results can ultimately inform clinical practice. Second, to benefit from being a platform trial, more standardisation between domains is required than in comparable stand-alone trials. Consequently, some compromises compared to the ideal stand-alone trial may be necessary in *INCEPT* domains. Importantly, *INCEPT* allows and encourages co-enrolment with other trials. As such, stand-alone trials can still be conducted alongside *INCEPT* for research questions where the compromises necessary would be deemed too large for a research question to be answered optimally within *INCEPT*. Third, the use of adaptive features increases complexity, and all adaptive features may not always be beneficial.^{21, 57, 58} By evaluating key methodological decisions in domains through extensive statistical simulation,⁴⁴ we will ensure that the added complexity of all adaptive choices measures up to their benefits and that adaptations are only used to the extent they are deemed overall advantageous. Finally, *time drift*^{9, 17, 53}—potential bias due to changes over time in allocation probabilities and in the included populations or concomitant care—may pose a challenge and introduce bias in advanced adaptive trials if not adequately handled. Consequently, *INCEPT* adjusts all analyses for time period and only includes concurrent controls in all comparisons.

4 | CONCLUSIONS

INCEPT provides an efficient and flexible platform for comparing the effects of many interventions used in adult ICU patients. The perpetual nature of the platform facilitates the establishment of lasting, improved trial infrastructure, including *embedding* the trial in both clinical practice and electronic patient records to enable (partially) automated data collection to reduce labor and cost. The use of large maximum sample sizes and advanced adaptive features ensures high probabilities of conclusiveness and enables the trial to use accumulating data to improve the treatment of future participants. The pragmatic design and advanced adaptive features mean that *INCEPT* will provide high-certainty, conclusive evidence for many interventions. *INCEPT* will thus enable the assessment of many interventions in critically ill adult ICU patients and will provide conclusive evidence that can directly inform practice and improve patient-important outcomes.

AUTHOR CONTRIBUTIONS

Conceptualisation: AG, MHM, TL, AP. **Funding acquisition:** AG, MHM, TSM, FK, PR, TL, AP. **Investigation:** all authors. **Methodology:** All authors. **Project administration:** AG, MHM, BSKH, MBNK, TSM, RFL, AP. **Software:** AG, BSKH, AKGJ, TL. **Supervision:** MHM, AKGJ, TL, AP. **Visualization:** AG. **Writing—original draft:** AG. **Writing—review and editing:** All authors.

AFFILIATIONS

- ¹Department of Intensive Care, Copenhagen University Hospital—Rigshospitalet, Copenhagen, Denmark
- ²Section of Biostatistics, Department of Public Health, University of Copenhagen, Copenhagen, Denmark
- ³Collaboration for Research in Intensive Care (CRIC), Copenhagen, Denmark
- ⁴Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
- ⁵Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
- ⁶Department of Anesthesiology and Intensive Care, Aarhus University Hospital, Aarhus, Denmark
- ⁷Prehospital Emergency Medical Services, Central Region Denmark, Aarhus, Denmark
- ⁸Department of Anaesthesia and Intensive Care, Aalborg University Hospital, Aalborg, Denmark
- ⁹Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
- ¹⁰Department of Anaesthesiology and Intensive Care, Zealand University Hospital, Køge, Denmark
- ¹¹Department of Anaesthesia and Critical Care Medicine, Odense University Hospital, Odense, Denmark
- ¹²Department of Anaesthesia and Critical Care Medicine, Hospital Sønderjylland, University Hospital of Southern Denmark, Odense, Denmark
- ¹³Department of Critical Care, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

¹⁴Steno Diabetes Center Copenhagen, Herlev, Denmark

¹⁵Department of Anaesthesia and Intensive Care, Lillebælt Hospital, Kolding, Denmark

¹⁶Department of Anesthesiology and Intensive Care, Bispebjerg and Frederiksberg Hospitals, Copenhagen, Denmark

¹⁷Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden

¹⁸Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden

¹⁹Department of Anaesthesia and Intensive Care Medicine, Division of Emergencies and Critical Care, Rikshospitalet, Oslo University Hospital, Oslo, Norway

²⁰Department of Research and Development, Division of Emergencies and Critical Care, Rikshospitalet, Oslo University Hospital, Oslo, Norway

²¹Department of Intensive Care, Tampere University Hospital, Wellbeing Services County of Pirkanmaa and Tampere University, Tampere, Finland

²²Department of Intensive Care Medicine, Inselspital, University Hospital Bern, Bern, Switzerland

²³Intensive Care Unit, University Hospital Basel, Basel, Switzerland

²⁴Faculty of Medicine, University of Iceland, Reykjavik, Iceland

²⁵Department of Anesthesiology and Critical Care Medicine, Landspítali—the National University Hospital of Reykjavik, Reykjavik, Iceland

²⁶Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen, Denmark

FUNDING INFORMATION

INCEPT is funded by the *Novo Nordisk Foundation* and *Sygeforsikringen 'danmark'*, with additional support from *Grosserer Jakob Ehrenreich og Hustru Grete Ehrenreichs Fond*, *Dagmar Marshalls Fond*, and *Savværksejer Jeppe Juhl og hustru Ovita Juhls Mindelegat*. The *INCEPT-Albumin* domain is partially funded by *Danmarks Frie Forskningsfond*. None of the funders have had any influence on the planning of the platform trial, and none will have any influence on the design, conduct, analysis, or reporting of any domains assessed on the platform. None of the funders will have ownership of any trial data.

CONFLICT OF INTEREST STATEMENT

Bodil Steen Rasmussen: unrestricted grant from the Novo Nordisk Foundation for long-term follow-up in the Handling Oxygenation Targets in the Intensive Care Unit (HOT-ICU) trial (ended June 2024). Tine Sylvest Meyhoff: coordinating investigator of the CLASSIC trial (NCT03668236) which was supported by a grant (NNF17OC0028608) from the Novo Nordisk Foundation and by the Sofus Friis' Foundation, Rigshospitalet's Research Council, and supported by the Danish Society of Anesthesiology and Intensive Care Medicine. Hans-Christian Thorsen-Meyer: research grant from the Novo Nordisk Foundation (NNF19OC0054863). Marie Oxenbøll Collet: the Novo Nordisk Foundation, Grant NNF21OC0072048 Postdoc fellowships in Nursing Research 2021. Ole Mathiesen: funding to research group from the Novo Nordisk Foundation and

Sygeforsikringen 'danmark' for other projects. Mathias Maagaard: holds shares in Novo Nordisk. Peter Rossing: grants for investigator-initiated studies to Steno Diabetes Center Copenhagen, from Novo Nordisk, Bayer, AstraZeneca, and Lexicon. Honoraria to Steno Diabetes Center Copenhagen for steering group membership, consultancy, and education from AstraZeneca, Abbott, Bayer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Gilead, and Sanofi. No personal honoraria and no shares/patents. Asger Granfeldt: paid member of data safety monitoring board for Noorik Pharmaceuticals (ended November 2022), work for hire for NMD Pharma, and task force member of the International Liaison Committee on Resuscitation (ILCOR) advanced life support task force. Theis Skovsgaard Itenov: the Department of Anaesthesiology and Intensive Care, Copenhagen University Hospital—Bispebjerg and Frederiksberg Hospital has a collaboration with Radiometer Medical Denmark on the testing and evaluation of equipment. The department receives reimbursements from the company. No individual receives any personal benefits or payments from the collaboration. Johanna Hästbacka: advisory board honorary fee from Paion (2022). Carmen Andrea Pfortmueller: no personal conflict of interests (personal financial interest). The department of Intensive Care at Inselspital, University Hospital of Bern reports grants from Orion Pharma, Abbott Nutrition International, B. Braun Medical AG, CSEM AG, Edwards Lifesciences Services GmbH, Kenta Biotech Ltd., Maquet Critical Care AB, Omnicare Clinical Research AG, Nestle, Pierre Fabre Pharma AG, Pfizer, Bard Medica S.A., Abbott AG, Anandic Medical Systems, Pan Gas AG Healthcare, Bracco, Hamilton Medical AG, Fresenius Kabi, Getinge Group Maquet AG, Dräger AG, Teleflex Medical GmbH, Glaxo Smith Kline, Merck Sharp and Dohme AG, Eli Lilly and Company, Baxter, Astellas, Astra Zeneca, CSL Behring, Novartis, Covidien, and Nycomed outside the submitted work. The money was paid into departmental funds; no personal financial gain applied. Davide Placido: holds stocks in Novo Nordisk. Theis Lange: served on data safety monitoring boards in studies run by Novo Nordisk and Leo Pharma. Anders Perner: research grants from the Novo Nordisk Foundation. All other authors: no relevant conflicts of interest.

DATA AVAILABILITY STATEMENT

No patient data were analysed in this protocol manuscript. Data sharing plans for the trial are described in the full protocol available at the trial website.

ORCID

Anders Granholm <https://orcid.org/0000-0001-5799-7655>

Benjamin Skov Kaas-Hansen <https://orcid.org/0000-0003-1023-0371>

Marie Warrer Munch <https://orcid.org/0000-0003-1127-9599>

Maj-Brit Nørregaard Kjær <https://orcid.org/0000-0002-6536-0504>

Lars Wiuff Andersen <https://orcid.org/0000-0001-5752-8082>

Olav Lilleholt Schjørring <https://orcid.org/0000-0002-7749-6003>

Bodil Steen Rasmussen <https://orcid.org/0000-0003-2190-145X>

Tine Sylvest Meyhoff <https://orcid.org/0000-0002-1840-1596>

Marie Oxenbøll Collet <https://orcid.org/0000-0002-8387-3960>

Nick Frørup Meier <https://orcid.org/0009-0006-4761-3228>

Ole Mathiesen <https://orcid.org/0000-0003-4544-0619>

Mathias Maagaard <https://orcid.org/0000-0002-9037-7295>

Anne Craveiro Brächner <https://orcid.org/0000-0001-6453-6152>

Martin Siegemund <https://orcid.org/0000-0002-2013-4140>

Theis Lange <https://orcid.org/0000-0002-1204-3636>

REFERENCES

- Dansk Intensiv Database. Årsrapport 2024. 2024. www.sundk.dk Accessed February 27, 2025.
- Laake JH, Dybwik K, Flaatten HK, et al. Impact of the post-world war II generation on intensive care needs in Norway. *Acta Anaesthesiol Scand*. 2010;54:479-484. doi:10.1111/j.1399-6576.2009.02170.x
- Fowler RA, Adhikari NKJ, Bhagwanjee S. Clinical review: critical care in the global context—disparities in burden of illness, access, and economics. *Crit Care*. 2008;12:225. doi:10.1186/cc6984
- Adhikari NKJ, Fowler RA, Bhagwanjee S, Rubenfeld GD. Critical care and the global burden of critical illness in adults. *The Lancet*. 2010;376:1339-1346. doi:10.1016/S0140-6736(10)60446-1
- Zhang Z, Hong Y, Liu N. Scientific evidence underlying the recommendations of critical care clinical practice guidelines: a lack of high level evidence. *Intensive Care Med*. 2018;44:1189-1191. doi:10.1007/s00134-018-5142-8
- Santacruz CA, Pereira AJ, Celis E, Vincent J-L. Which multicenter randomized controlled trials in critical care medicine have shown reduced mortality? A systematic review. *Crit Care Med*. 2019;47:1680-1691. doi:10.1097/CCM.0000000000004000
- Landoni G, Comis M, Conte M, et al. Mortality in multicenter critical care trials. *Crit Care Med*. 2015;43:1559-1568. doi:10.1097/CCM.0000000000000974
- Perner A, Finfer S. Do trials that report a neutral or negative treatment effect improve the care of critically ill patients? Yes. *Intensive Care Med*. 2018;44:1985-1988. doi:10.1007/s00134-018-5129-5
- Granholt A, Alhazzani W, Derde LPG, et al. Randomised clinical trials in critical care: past, present and future. *Intensive Care Med*. 2022;48:164-178. doi:10.1007/s00134-021-06587-9
- Kapadia FN, Kapoor R, Trivedi M. Can less be more in intensive care? *Indian J Crit Care Med*. 2017;21:1-5. doi:10.4103/0972-5229.198308
- Ridgeon EE, Bellomo R, Abernethy SK, et al. Effect sizes in ongoing randomized controlled critical care trials. *Crit Care*. 2017;21:132. doi:10.1186/s13054-017-1726-x
- Harhay MO, Wagner J, Ratcliffe SJ, et al. Outcomes and statistical power in adult critical care randomized trials. *Am J Respir Crit Care Med*. 2014;189:1469-1478. doi:10.1164/rccm.201401-0056CP
- Cuthbertson BH, Scales DC. "Paying the piper": the downstream implications of manipulating sample size assumptions for critical care randomized control trials. *Crit Care Med*. 2020;48:1885-1886. doi:10.1097/CCM.0000000000004664
- Abrams D, Montesi SB, Moore SKL, et al. Powering bias and clinically important treatment effects in randomized trials of critical illness. *Crit Care Med*. 2020;48:1710-1719. doi:10.1097/CCM.0000000000004568
- Saha R, Assouline B, Mason G, Douiri A, Summers C, Shankar-Hari M. The impact of sample size misestimations on the interpretation of ARDS trials. *Chest*. 2022;162:1048-1062. doi:10.1016/j.chest.2022.05.018
- Altman DG, Bland JM. Absence of evidence is not evidence of absence. *BMJ*. 1995;311:485. doi:10.1136/bmj.311.7003.485
- Adaptive Platform Trials Coalition. Adaptive platform trials: definition, design, conduct and reporting considerations. *Nat Rev Drug Discov*. 2019;18:797-807. doi:10.1038/s41573-019-0034-3
- Pitre T, Cheng S, Cusano E, et al. Methodology and design of platform trials: a meta-epidemiological study. *J Clin Epidemiol*. 2023;157:1-12. doi:10.1016/j.jclinepi.2023.02.010

19. Noor NM, Love SB, Isaacs T, Kaplan R, Parmar MKB, Sydes MR. Uptake of the multi-arm multi-stage (MAMS) adaptive platform approach: a trial-registry review of late-phase randomised clinical trials. *BMJ Open*. 2022;12:e055615. doi:10.1136/bmjopen-2021-055615
20. PRACTICAL, PANTHER, TRAITS, INCEPT and REMAP-CAP investigators. The rise of adaptive platform trials in critical care. *Am J Respir Crit Care Med*. 2024;209:491-496. doi:10.1164/rccm.202401-0101CP
21. Granholm A, Kaas-Hansen BS, Lange T, et al. An overview of methodological considerations regarding adaptive stopping, arm dropping, and randomization in clinical trials. *J Clin Epidemiol*. 2023;153:45-54. doi:10.1016/j.jclinepi.2022.11.002
22. van Werkhoven CH, Harbarth S, Bonten MJM. Adaptive designs in clinical trials in critically ill patients: principles, advantages and pitfalls. *Intensive Care Med*. 2019;45:678-682. doi:10.1007/s00134-018-5426-z
23. Park JJH, Sharif B, Harari O, et al. Economic evaluation of cost and time required for a platform trial vs conventional trials. *JAMA Netw Open*. 2022;5:e2221140. doi:10.1001/jamanetworkopen.2022.21140
24. Saville BR, Berry SM. Efficiencies of platform clinical trials: a vision of the future. *Clin Trials*. 2016;13:358-366. doi:10.1177/1740774515626362
25. Parmar MKB, Carpenter J, Sydes MR. More multiarm randomised trials of superiority are needed. *Lancet*. 2014;384:283-284. doi:10.1016/S0140-6736(14)61122-3
26. Hobbs BP, Chen N, Lee JJ. Controlled multi-arm platform design using predictive probability. *Stat Methods Med Res*. 2018;27:65-78. doi:10.1177/0962280215620696
27. Granholm A. Establishing a Bayesian adaptive platform trial in critical care. PhD thesis. University of Copenhagen 2024. doi:10.5281/zenodo.10931287
28. Granholm A, Munch MW, Meier N, et al. Empirical meropenem versus piperacillin/tazobactam for adult patients with sepsis (EMPRESS) trial: protocol. *Acta Anaesthesiol Scand*. 2024;68:1107-1119. doi:10.1111/aas.14441
29. Chan A-W, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. *Ann Intern Med*. 2013;158:200-207. doi:10.7326/0003-4819-158-3-201302050-00583
30. Dimairo M, Pallmann P, Wason J, et al. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. *BMJ*. 2020;369:m115. doi:10.1136/bmj.m115
31. Indenrigs- og Sundhedsministeriet. Bekendtgørelse om kliniske forsøg med lægemidler (BEK nr 12 af 06/01/2022). Retsinformation. 2022. <https://www.retsinformation.dk/eli/lta/2022/12> Accessed: February 27, 2025.
32. The European Parliament and the Council of the European Union. Regulation (EU) No 536/2014 of the European Parliament and of the Council. Official Journal of the European Union. 2014. <https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX%3A32014R0536> Accessed: February 27, 2025.
33. World Medical Association. World medical association declaration of Helsinki. *JAMA*. 2024;81:14-18. doi:10.1001/jama.2024.21972
34. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Statistical Principles for Clinical Trials E9. Current Step 4 version. 1998. https://database.ich.org/sites/default/files/E9_Guideline.pdf Accessed: February 27, 2025.
35. World Health Organization. Guidance for best practices for clinical trials. 2024. <https://www.who.int/publications/i/item/9789240097711> Accessed: February 27, 2025.
36. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res*. 2011;20:1727-1736. doi:10.1007/s11136-011-9903-x
37. MoCA Test Inc. MoCA Cognition. 2024. <https://mocacognition.com> Accessed: May 16, 2024.
38. Nasreddine ZS. MoCA Test: validation of a five-minute telephone version. *Alzheimers Dement*. 2021;17:e057817. doi:10.1002/alz.057817
39. EudraLex - EU Legislation. Risk proportionate approaches in clinical trials - Recommendations of the expert group on clinical trials for the implementation of Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use. *EudraLex - Volume 10 - Clinical Trials Guidelines*. 2017. https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-10_en Accessed: February 27, 2025.
40. Granholm A, Kaas-Hansen BS, Lange T, et al. Use of days alive without life support and similar count outcomes in randomised clinical trials—an overview and comparison of methodological choices and analysis methods. *BMC Med Res Methodol*. 2023;23:139. doi:10.1186/s12874-023-01963-z
41. Granholm A, Anthon CT, Kjær M-BN, et al. Patient-important outcomes other than mortality in contemporary ICU trials: a scoping review. *Crit Care Med*. 2022;50:e759-e771. doi:10.1097/CCM.0000000000005637
42. Kjær M-BN, Bruun CRL, Granholm A, et al. A Core outcome set for adult general ICU patients. *Crit Care Med*. 2025;53:e575-e589. doi:10.1097/CCM.0000000000006556
43. Kjær MN, Granholm A, Vesterlund GK, et al. Development of a core outcome set for general intensive care unit patients—a protocol. *Acta Anaesthesiol Scand*. 2022;66(3):415-424. doi:10.1111/aas.14024
44. Granholm A, Jensen AKG, Lange T, Perner A, Møller MH, Kaas-Hansen BS. Designing and evaluating advanced adaptive randomised clinical trials: a practical guide. 2025 ArXiv: 2501.08765. doi:10.48550/arXiv.2501.08765
45. Altman DG, Bland JM. Statistics notes: how to randomise. *BMJ*. 1999;319:703-704. doi:10.1136/bmj.319.7211.703
46. Granholm A, Perner A, Krag M, et al. Development and internal validation of the simplified mortality score for the intensive care unit (SMS-ICU). *Acta Anaesthesiol Scand*. 2018;62:336-346. doi:10.1111/aas.13048
47. Rockwood K. A global clinical measure of fitness and frailty in elderly people. *Can Med Assoc J*. 2005;173:489-495. doi:10.1503/cmaj.050051
48. Rockwood K, Theou O. Using the clinical frailty scale in allocating scarce health care resources. *Can Geriatr J*. 2020;23:254-259. doi:10.5770/cgj.23.463
49. Goligher EC, Heath A, Harhay MO. Bayesian statistics for clinical research. *Lancet*. 2024;404:1067-1076. doi:10.1016/S0140-6736(24)01295-9
50. Vanderbeek AM, Bliss JM, Yin Z, Yap C. Implementation of platform trials in the COVID-19 pandemic: a rapid review. *Contemp Clin Trials*. 2022;112:106625. doi:10.1016/j.cct.2021.106625
51. United States Food and Drug Administration. Adaptive Designs for Clinical Trials of Drugs and Biologics - Guidance for Industry. Guidance Document. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adaptive-design-clinical-trials-drugs-and-biologics-guidance-industry> 2019 Accessed: February 27, 2025.
52. Fergusson D, Aaron SD, Guyatt G, Hébert P. Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis. *BMJ*. 2002;325:652-654. doi:10.1136/bmj.325.7365.652
53. Park JJH, Detry MA, Murthy S, Guyatt G, Mills EJ. How to use and interpret the results of a platform trial. *JAMA*. 2022;327:67. doi:10.1001/jama.2021.22507
54. European Medicines Agency. ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. 2020. <https://www.ema.europa.eu/en/ich-e9-statistical-principles-clinical-trials-scientific-guideline> Accessed: February 27, 2025.

55. Kahan BC, Hindley J, Edwards M, Cro S, Morris TP. The estimands framework: a primer on the ICH E9(R1) addendum. *BMJ*. 2024;384:e076316. doi:[10.1136/bmj-2023-076316](https://doi.org/10.1136/bmj-2023-076316)
56. Granholm A, Lange T, Harhay MO, et al. Effects of duration of follow-up and lag in data collection on the performance of adaptive clinical trials. *Pharm Stat*. 2024;23:138-150. doi:[10.1002/pst.2342](https://doi.org/10.1002/pst.2342)
57. Pallmann P, Bedding AW, Choodari-Oskooei B, et al. Adaptive designs in clinical trials: why use them, and how to run and report them. *BMC Med*. 2018;16:29. doi:[10.1186/s12916-018-1017-7](https://doi.org/10.1186/s12916-018-1017-7)
58. Robertson DS, Lee KM, López-Kolkovska BC, Villar SS. Response-adaptive randomization in clinical trials: from myths to practical considerations. *Stat Sci*. 2023;38:185-208. doi:[10.1214/22-STS865](https://doi.org/10.1214/22-STS865)
59. United States Food and Drug Administration. Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products. Guidance Document. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adjusting-covariates-randomized-clinical-trials-drugs-and-biological-products> 2023 Accessed: February 27, 2025.
60. Granholm A, Lange T, Harhay MO, Perner A, Møller MH, Kaas-Hansen BS. Effects of sceptical priors on the performance of adaptive clinical trials with binary outcomes. *Pharm Stat*. 2024;23:728-741. doi:[10.1002/pst.2387](https://doi.org/10.1002/pst.2387)
61. Jansen JO, Wang H, Holcomb JB, et al. Elicitation of prior probability distributions for a proposed Bayesian randomized clinical trial of whole blood for trauma resuscitation. *Transfusion*. 2020;60:498-506. doi:[10.1111/trf.15675](https://doi.org/10.1111/trf.15675)
62. Iwashyna TJ, Burke JF, Sussman JB, Prescott HC, Hayward RA, Angus DC. Implications of heterogeneity of treatment effect for reporting and analysis of randomized trials in critical care. *Am J Respir Crit Care Med*. 2015;192:1045-1051. doi:[10.1164/rccm.201411-2125CP](https://doi.org/10.1164/rccm.201411-2125CP)
63. van Buuren S. *Flexible Imputation of Missing Data*. 2nd ed. CRC Press; 2018 <https://stefvanbuuren.name/fimd/>
64. Jakobsen JC, Gluud C, Wetterslev J, Winkel P. When and how should multiple imputation be used for handling missing data in randomised clinical trials—a practical guide with flowcharts. *BMC Med Res Methodol*. 2017;17:162. doi:[10.1186/s12874-017-0442-1](https://doi.org/10.1186/s12874-017-0442-1)
65. Granholm A, Jensen AKG, Lange T, Kaas-Hansen BS. Adaptr: an R package for simulating and comparing adaptive clinical trials. *J Open Source Softw*. 2022;7:4284. doi:[10.21105/joss.04284](https://doi.org/10.21105/joss.04284)
66. Zarbock A, Forni LG, Koyner JL, et al. Recommendations for clinical trial design in acute kidney injury from the 31st acute disease quality initiative consensus conference. A consensus statement. *Intensive Care Med*. 2024;50(9):1426-1437. doi:[10.1007/s00134-024-07560-y](https://doi.org/10.1007/s00134-024-07560-y)
67. Angus DC. Optimizing the trade-off between learning and doing in a pandemic. *JAMA*. 2020;323:1895-1896. doi:[10.1001/jama.2020.4984](https://doi.org/10.1001/jama.2020.4984)
68. Anthon CT, Granholm A, Perner A, Laake JH, Møller MH. Overall bias and sample sizes were unchanged in ICU trials over time: a meta-epidemiological study. *J Clin Epidemiol*. 2019;113:189-199. doi:[10.1016/j.jclinepi.2019.05.021](https://doi.org/10.1016/j.jclinepi.2019.05.021)

How to cite this article: Granholm A, Møller MH, Kaas-Hansen BS, et al. INCEPT: The Intensive Care Platform Trial—Design and protocol. *Acta Anaesthesiol Scand*. 2025; 69(4):e70023. doi:[10.1111/aas.70023](https://doi.org/10.1111/aas.70023)